Global Cardiac Valve Market – Industry Trends and Forecast to 2031

Analyse et taille du marché des valves cardiaques

La chirurgie de remplacement valvulaire est une application essentielle sur le marché des valves cardiaques, essentielle pour traiter les maladies valvulaires graves où la valve naturelle est endommagée ou dysfonctionnelle. Cette intervention chirurgicale consiste à remplacer la valve cardiaque affectée par une valve mécanique fabriquée à partir de matériaux durables tels que le métal ou par une valve biologique dérivée de tissus animaux ou de donneurs humains. Le choix entre les valves mécaniques et biologiques dépend de facteurs tels que l'âge, le mode de vie et les antécédents médicaux du patient. La chirurgie valvulaire cardiaque vise à rétablir un flux sanguin adéquat dans le cœur, à soulager les symptômes tels que l'essoufflement et la fatigue, et à améliorer la fonction cardiaque globale, améliorant ainsi la qualité de vie du patient et réduisant la mortalité associée aux maladies valvulaires graves.

Français La taille du marché mondial des valves cardiaques était évaluée à 11,34 milliards USD en 2023 et devrait atteindre 27,09 milliards USD d'ici 2031, avec un TCAC de 11,5 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée du rapport et segmentation du marché       

Définition du marché

Les valvules cardiaques sont des structures situées à l'intérieur du cœur qui régulent le flux sanguin en s'ouvrant et en se fermant pour assurer la circulation du sang dans la bonne direction. Le cœur est composé de quatre valvules principales : la valvule mitrale, la valvule tricuspide, la valvule aortique et la valvule pulmonaire. Ces valvules s'ouvrent pour permettre le passage du sang et se ferment pour empêcher le reflux, maintenant ainsi une circulation efficace dans tout le corps. Un dysfonctionnement ou une maladie de ces valvules peut entraîner de graves problèmes cardiovasculaires nécessitant une intervention médicale.

Dynamique du marché des valves cardiaques

Conducteurs

• Prévalence croissante des maladies liées au mode de vie

La prévalence des maladies liées au mode de vie, telles que l’obésité, le diabète et l’hypertension, contribue au développement et à la progression des maladies cardiovasculaires, notamment des troubles valvulaires, qui nécessitent souvent des interventions chirurgicales telles que le remplacement ou la réparation des valves. Des facteurs liés au mode de vie, tels qu’une alimentation malsaine, l’inactivité physique et le stress, contribuent à l’incidence croissante de ces maladies à l’échelle mondiale. Comme ces facteurs de risque liés au mode de vie continuent d’affecter un segment plus large de la population, la demande de chirurgies valvulaires cardiaques et de traitements associés devrait augmenter.                                                                   

• Vieillissement de la population

La population vieillissante est plus susceptible de développer des maladies des valves cardiaques telles que la sténose aortique et la régurgitation mitrale en raison de l'usure des valves cardiaques au fil du temps. Cette tendance démographique se traduit par une prévalence plus élevée des troubles valvulaires, nécessitant des interventions chirurgicales telles que le remplacement ou la réparation des valves. Le nombre croissant de personnes âgées qui consultent pour ces pathologies crée une demande importante de procédures valvulaires cardiaques et de technologies associées. Par conséquent, les prestataires de soins de santé et les fabricants de dispositifs médicaux consacrent davantage de ressources au développement de traitements innovants et à l'amélioration des résultats chirurgicaux pour répondre aux besoins croissants de ce groupe démographique.

Opportunités

• Des progrès technologiques croissants

Innovations in valve materials, such as bioabsorbable polymers and tissue-engineered valves, offer durable and biocompatible alternatives to traditional prosthetics. Moreover, advancements in imaging technologies, such as 3D echocardiography and cardiac MRI, enhance pre-operative planning and intraoperative guidance, leading to more precise surgeries and reduced complications. Minimally invasive techniques, such as transcatheter valve replacement (TAVR), have also revolutionized treatment by offering less invasive options for high-risk patients, reducing recovery times and hospital stays. These technological strides expand treatment possibilities and contribute to the overall growth and evolution of the cardiac valve market globally.

• Rising Healthcare Expenditure

Increased investment in healthcare infrastructure and services allows for greater accessibility to advanced cardiac treatments, including valve replacement surgeries. This financial support enables hospitals and healthcare facilities to procure state-of-the-art equipment, employ skilled medical professionals, and offer comprehensive cardiac care to a larger patient population. Higher healthcare spending fosters research and development in cardiovascular medicine, leading to innovations in valve technologies and surgical techniques. As economies grow and healthcare budgets expand, patients benefit from improved treatment outcomes and reduced mortality rates associated with cardiac valve diseases, reinforcing the market's growth trajectory.

Restraints/Challenges

• High Cost of Cardiac Valve Procedures

Valve replacement surgeries, whether using mechanical or biological valves, involve substantial expenses related to hospitalization, surgical equipment, anesthesia, and post-operative care. These costs can be prohibitive for patients without adequate insurance coverage or in regions with limited healthcare funding. Additionally, the pricing of prosthetic valves themselves contributes to the overall expense, particularly for newer technologies or biocompatible materials. High procedural costs may deter patients from seeking timely treatment or opting for alternative, less costly management strategies, impacting market demand and growth potential.

• Alternative Treatment Options

Alternative treatment options for less severe valve disorders or patients unwilling or unable to undergo surgical interventions. These alternatives include medication to manage symptoms such as blood thinners or medications to reduce blood pressure, as well as lifestyle modifications such as diet and exercise changes. Non-surgical procedures such as valvuloplasty (balloon valvuloplasty) offer a less invasive option for some patients but may not provide a permanent solution compared to surgical valve replacement. The availability and effectiveness of these alternatives can reduce the demand for surgical interventions, impacting the growth potential of the cardiac valve market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In September 2019, Medtronic launched the Evolut PRO+ transcatheter aortic valve replacement (TAVR) system in the U.S. TAVR is a minimally invasive procedure used to treat severe aortic stenosis in patients who are at high risk for traditional open-heart surgery. The Evolut PRO+ system builds upon previous generations with enhanced features aimed at improving valve performance and patient outcomes, expanding treatment options for individuals with severe aortic valve disease
• In September 2019, Abbott initiated the TRILUMINATE pivotal trial for its TriClip transcatheter tricuspid valve repair system. This system is designed to address tricuspid regurgitation, a condition where blood flows backward into the right atrium due to improper closure of the tricuspid valve. The TriClip procedure aims to reduce regurgitation and improve heart function without the need for open-heart surgery, offering a less invasive treatment option for patients suffering from this challenging valve disorder

Cardiac Valve Market Scope

The market is segmented on the basis of type, treatment, position and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Cardiac Valve Repair
• Cardiac Valve Replacement

Position

• Mitral Valve
• Aortic Valve
• Other Position

Type

• Trans-Catheter Heart Valve
• Tissue Heart Valve
• Mechanical Heart Valve
• Others

End-user

• Cardiac Research Institute
• Hospital and Clinics
• Speciality centers
• Others

Cardiac Valve Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, type, treatment, position and end-user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.

North America dominates the market due to its high incidence of cardiac disorders, bolstered by widespread adoption of advanced cardiac devices. The region benefits from robust healthcare infrastructure, facilitating early diagnosis and treatment. These factors contribute to a greater demand for cardiac valves, which are crucial in managing and treating various cardiac conditions prevalent in the population. Consequently, North America remains at the forefront of innovation and market growth in the cardiac valve sector.

Asia-Pacific is expected to experience significant growth in the market due to increasing elderly population, leading to higher demand for healthcare services and products. Additionally, changing lifestyles, characterized by rising incidences of chronic diseases, contribute to the healthcare sector's expansion. Moreover, the region is becoming a hub for medical tourism, attracting patients from around the world seeking affordable and high-quality healthcare services. These dynamics position Asia-Pacific as a pivotal region for healthcare growth in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Cardiac Valve Market Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Medtronic (Ireland)
• LivaNova PLC (U.K)
• Abbott (U.S)
• Colibri Heart Valve (U.S)
• On-X Life Technologies Inc. (U.S)
• TTK (Chennai)
• JenaValve Technology Inc. (U.S)
• CryoLife Inc (U.S)
• Boston Scientific Corporation (U.S)
• Edwards Lifesciences Corporation (U.S)
• Symetis (Switzerland)
• Lepu Medical Technology(Beijing)Co.,Ltd. (China)
• Braile Biomédica (Brazil)
• Micro Interventional Devices, Incorporated (U.S)
• Auto Tissue Berlin GmbH (Germany)

SKU-53284